KR20170043597A - 루카파립의 고 용량 강도 정제 - Google Patents

루카파립의 고 용량 강도 정제 Download PDF

Info

Publication number
KR20170043597A
KR20170043597A KR1020177007284A KR20177007284A KR20170043597A KR 20170043597 A KR20170043597 A KR 20170043597A KR 1020177007284 A KR1020177007284 A KR 1020177007284A KR 20177007284 A KR20177007284 A KR 20177007284A KR 20170043597 A KR20170043597 A KR 20170043597A
Authority
KR
South Korea
Prior art keywords
tablet
camsylate
active ingredient
mammal
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177007284A
Other languages
English (en)
Korean (ko)
Inventor
제프리 에터
Original Assignee
클로비스 온콜로지 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클로비스 온콜로지 인코포레이티드 filed Critical 클로비스 온콜로지 인코포레이티드
Priority to KR1020237020594A priority Critical patent/KR102803917B1/ko
Publication of KR20170043597A publication Critical patent/KR20170043597A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177007284A 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제 Ceased KR20170043597A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237020594A KR102803917B1 (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US62/040,849 2014-08-22
US201562101739P 2015-01-09 2015-01-09
US62/101,739 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237020594A Division KR102803917B1 (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제

Publications (1)

Publication Number Publication Date
KR20170043597A true KR20170043597A (ko) 2017-04-21

Family

ID=55347324

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177007284A Ceased KR20170043597A (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제
KR1020237020594A Active KR102803917B1 (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237020594A Active KR102803917B1 (ko) 2014-08-22 2015-08-17 루카파립의 고 용량 강도 정제

Country Status (24)

Country Link
US (3) US9987285B2 (enExample)
EP (1) EP3182975B1 (enExample)
JP (3) JP6574477B2 (enExample)
KR (2) KR20170043597A (enExample)
CN (2) CN106794185A (enExample)
AU (2) AU2015305696B2 (enExample)
BR (1) BR112017000865A2 (enExample)
CA (1) CA2955495C (enExample)
DK (1) DK3182975T3 (enExample)
ES (1) ES3048688T3 (enExample)
FI (1) FI3182975T3 (enExample)
HR (1) HRP20251484T1 (enExample)
IL (1) IL249946B (enExample)
LT (1) LT3182975T (enExample)
MX (1) MX367260B (enExample)
NZ (1) NZ728392A (enExample)
PL (1) PL3182975T3 (enExample)
PT (1) PT3182975T (enExample)
RS (1) RS67356B1 (enExample)
RU (1) RU2705156C2 (enExample)
SG (1) SG11201700265VA (enExample)
SI (1) SI3182975T1 (enExample)
SM (1) SMT202600141T1 (enExample)
WO (1) WO2016028689A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US10117836B2 (en) 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
KR20170043597A (ko) * 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
EP3573990B1 (en) 2017-01-24 2024-07-10 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
CN111278433A (zh) * 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
WO2020113500A1 (zh) * 2018-12-06 2020-06-11 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
KR20220035925A (ko) 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
ES3051838T3 (en) 2020-07-14 2025-12-30 Assia Chem Ind Ltd Solid state forms of rucaparib salts
MX2023001071A (es) 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
CN118215467A (zh) * 2021-11-10 2024-06-18 克里蒂泰克公司 鲁卡帕尼颗粒及其用途
WO2023137060A1 (en) 2022-01-11 2023-07-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140936B1 (en) 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
JP2006522088A (ja) 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
MXPA06000993A (es) 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
JP2008513435A (ja) 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
CA2580833C (en) 2004-09-22 2010-12-21 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
CA2581025C (en) 2004-09-22 2011-06-07 Pfizer Inc. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
US20110136883A1 (en) * 2008-04-09 2011-06-09 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
ES2607806T5 (es) * 2010-02-12 2024-10-07 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
KR20170043597A (ko) 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제

Also Published As

Publication number Publication date
SG11201700265VA (en) 2017-02-27
US20160051561A1 (en) 2016-02-25
AU2019272064A1 (en) 2019-12-19
NZ728392A (en) 2023-06-30
PT3182975T (pt) 2025-10-28
RU2017109139A3 (enExample) 2019-03-06
SMT202600141T1 (it) 2026-05-12
BR112017000865A2 (pt) 2017-12-05
EP3182975A1 (en) 2017-06-28
JP6574477B2 (ja) 2019-09-11
AU2015305696B2 (en) 2019-08-29
CA2955495A1 (en) 2016-02-25
FI3182975T3 (fi) 2025-11-13
CN113209033A (zh) 2021-08-06
DK3182975T3 (da) 2025-10-20
US10130636B2 (en) 2018-11-20
EP3182975A4 (en) 2018-04-18
SI3182975T1 (sl) 2025-12-31
IL249946A0 (en) 2017-03-30
JP6797980B2 (ja) 2020-12-09
AU2015305696A1 (en) 2017-02-02
US20190099430A1 (en) 2019-04-04
US20180200260A1 (en) 2018-07-19
HRP20251484T1 (hr) 2026-01-02
JP2021038242A (ja) 2021-03-11
EP3182975B1 (en) 2025-10-01
LT3182975T (lt) 2025-11-25
AU2019272064B2 (en) 2021-11-18
IL249946B (en) 2020-05-31
JP2017525712A (ja) 2017-09-07
MX2017001540A (es) 2017-05-11
RS67356B1 (sr) 2025-11-28
JP7127101B2 (ja) 2022-08-29
CN106794185A (zh) 2017-05-31
MX367260B (es) 2019-08-12
JP2020002149A (ja) 2020-01-09
RU2017109139A (ru) 2018-09-24
US9987285B2 (en) 2018-06-05
KR102803917B1 (ko) 2025-05-07
RU2705156C2 (ru) 2019-11-05
CA2955495C (en) 2023-09-19
KR20230097211A (ko) 2023-06-30
ES3048688T3 (en) 2025-12-11
PL3182975T3 (pl) 2026-02-23
WO2016028689A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
KR102803917B1 (ko) 루카파립의 고 용량 강도 정제
EP3606511B1 (en) Pharmaceutical composition comprising lenvatinib mesylate
KR20070046172A (ko) 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출성 정제 제형, 이의 제조방법 및 이의용도
JP7639092B2 (ja) 粒状組成物、粒状組成物の製造方法、および粒状組成物の溶出性改善方法
WO2013026553A1 (en) Composition comprising edoxaban
EP3860606B1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
US20140335176A1 (en) Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing
US20060222703A1 (en) Pharmaceutical composition and preparation method thereof
CN106456640A (zh) 色瑞替尼制剂
KR101532810B1 (ko) 당 알콜과 공동 미세화된 엔타카폰의 약학 조성물
JP2002012540A (ja) 水易溶性薬物含有錠剤
US20090215756A1 (en) Formulations containing losartan and/or its salts
HK1232807B (en) High dosage strength tablets of rucaparib
WO2015106960A1 (en) Pharmaceutical composition comprising a combination of a bisphosphonate and cholecalciferol and method for the preparation thereof
WO2007129522A1 (ja) 乾式製造法製剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170316

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200814

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220613

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230118

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220613

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230619